{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:10:52Z","timestamp":1792843852923,"version":"4.5.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02136-8","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T17:06:00Z","timestamp":1743267960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Progress of immune senescence in multiple myeloma treatment resistance"],"prefix":"10.1007","volume":"16","author":[{"given":"Yanan","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhexin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2136_CR1","doi-asserted-by":"publisher","first-page":"m3176","DOI":"10.1136\/bmj.m3176","volume":"370","author":"UA Shah","year":"2020","unstructured":"Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ. 2020;370:m3176. https:\/\/doi.org\/10.1136\/bmj.m3176.","journal-title":"BMJ"},{"issue":"10272","key":"2136_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ Van de Donk","year":"2021","unstructured":"Van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5.","journal-title":"Lancet"},{"key":"2136_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ebiom.2017.04.013","volume":"21","author":"JL Kirkland","year":"2017","unstructured":"Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017;21:21\u20138. https:\/\/doi.org\/10.1016\/j.ebiom.2017.04.013.","journal-title":"EBioMedicine"},{"issue":"12","key":"2136_CR4","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","volume":"6","author":"JP Copp\u00e9","year":"2008","unstructured":"Copp\u00e9 JP, Patil CK, Rodier F, Sun Y, Mu\u00f1oz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853\u201368. https:\/\/doi.org\/10.1371\/journal.pbio.0060301.","journal-title":"PLoS Biol"},{"issue":"1","key":"2136_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, Cheng Q, Luo P, Zhang Y, Han X. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;8(1):200. https:\/\/doi.org\/10.1038\/s41392-023-01451-2.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2136_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/s0002-9343(03)00329-2","volume":"115","author":"H Bruunsgaard","year":"2003","unstructured":"Bruunsgaard H, Andersen-Ranberg K, Hjelmborg JV, Pedersen BK, Jeune B. Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med. 2003;115(4):278\u201383. https:\/\/doi.org\/10.1016\/s0002-9343(03)00329-2.","journal-title":"Am J Med"},{"key":"2136_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1146\/annurev.med.51.1.245","volume":"51","author":"WB Ershler","year":"2000","unstructured":"Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245\u201370. https:\/\/doi.org\/10.1146\/annurev.med.51.1.245.","journal-title":"Annu Rev Med"},{"key":"2136_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12979-016-0076-x","volume":"13","author":"M Puzianowska-Ku\u017anicka","year":"2016","unstructured":"Puzianowska-Ku\u017anicka M, Owczarz M, Wieczorowska-Tobis K, Nadrowski P, Chudek J, Slusarczyk P, Skalska A, Jonas M, Franek E, Mossakowska M. Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. Immun Aging. 2016;13:21. https:\/\/doi.org\/10.1186\/s12979-016-0076-x.","journal-title":"Immun Aging"},{"issue":"9","key":"2136_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","volume":"15","author":"L Ferrucci","year":"2018","unstructured":"Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in aging, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018;15(9):505\u201322. https:\/\/doi.org\/10.1038\/s41569-018-0064-2.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"2136_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5483\/BMBRep.2020.53.2.291","volume":"53","author":"BC Lee","year":"2020","unstructured":"Lee BC, Yu KR. Impact of mesenchymal stem cell senescence on inflammaging. BMB Rep. 2020;53(2):65\u201373. https:\/\/doi.org\/10.5483\/BMBRep.2020.53.2.291.","journal-title":"BMB Rep"},{"issue":"50","key":"2136_CR11","doi-asserted-by":"publisher","first-page":"20012","DOI":"10.1073\/pnas.1116110108","volume":"108","author":"WW Pang","year":"2011","unstructured":"Pang WW, Price EA, Sahoo D, Beerman I, Maloney WJ, Rossi DJ, Schrier SL, Weissman IL. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA. 2011;108(50):20012\u20137. https:\/\/doi.org\/10.1073\/pnas.1116110108.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"26","key":"2136_CR12","doi-asserted-by":"publisher","first-page":"9194","DOI":"10.1073\/pnas.0503280102","volume":"102","author":"DJ Rossi","year":"2005","unstructured":"Rossi DJ, Bryder D, Zahn JM, Ahlenius H, Sonu R, Wagers AJ, Weissman IL. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci USA. 2005;102(26):9194\u20139. https:\/\/doi.org\/10.1073\/pnas.0503280102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2136_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.cell.2014.03.030","volume":"157","author":"CSN Klose","year":"2014","unstructured":"Klose CSN, Flach M, M\u00f6hle L, Rogell L, Hoyler T, Ebert K, Fabiunke C, Pfeifer D, Sexl V, Fonseca-Pereira D, Domingues RG, Veiga-Fernandes H, Arnold SJ, Busslinger M, Dunay IR, Tanriver Y, Diefenbach A. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell. 2014;157(2):340\u201356. https:\/\/doi.org\/10.1016\/j.cell.2014.03.030.","journal-title":"Cell"},{"issue":"6","key":"2136_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3390\/cells11061017","volume":"11","author":"A Brauning","year":"2022","unstructured":"Brauning A, Rae M, Zhu G, Fulton E, Admasu TD, Stolzing A, Sharma A. Aging of the immune system: focus on natural killer cells phenotype and functions. Cells. 2022;11(6):1017. https:\/\/doi.org\/10.3390\/cells11061017.","journal-title":"Cells"},{"key":"2136_CR15","doi-asserted-by":"publisher","first-page":"100494","DOI":"10.1016\/j.ctarc.2021.100494","volume":"29","author":"A Visram","year":"2021","unstructured":"Visram A, Kourelis TV. Aging-associated immune system changes in multiple myeloma: the dark side of the moon. Cancer Treat Res Commun. 2021;29:100494. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100494.","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"2136_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R, J\u00f6hrer K. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9(1):116. https:\/\/doi.org\/10.1186\/s13045-016-0345-3.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2136_CR17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00018-016-2135-z","volume":"73","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Nakamura K, Vuckovic S, Hill GR, Smyth MJ. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci. 2016;73(8):1569\u201389. https:\/\/doi.org\/10.1007\/s00018-016-2135-z.","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"2136_CR18","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3390\/cancers13061454","volume":"13","author":"D Damasceno","year":"2021","unstructured":"Damasceno D, Almeida J, Teodosio C, Sanoja-Flores L, Mayado A, P\u00e9rez-Pons A, Puig N, Arana P, Paiva B, Solano F, Romero A, Matarraz S, van den Bossche WBL, Flores-Montero J, Durie B, van Dongen JJM, Orfao A. Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma. Cancers. 2021;13(6):1454. https:\/\/doi.org\/10.3390\/cancers13061454.","journal-title":"Cancers"},{"issue":"6","key":"2136_CR19","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/ijms24065730","volume":"24","author":"A Kulikowska de Na\u0142\u0119cz","year":"2023","unstructured":"Kulikowska de Na\u0142\u0119cz A, Ciszak L, Usnarska-Zubkiewicz L, Pawlak E, Frydecka I, Szmyrka M, Kosmaczewska A. Inappropriate expression of PD-1 and CTLA-4 checkpoints in myeloma patients is more pronounced at diagnosis: implications for time to progression and response to therapeutic checkpoint inhibitors. Int J Mol Sci. 2023;24(6):5730. https:\/\/doi.org\/10.3390\/ijms24065730.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2136_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.smim.2012.04.004","volume":"24","author":"I Kogut","year":"2012","unstructured":"Kogut I, Scholz JL, Cancro MP, Cambier JC. B cell maintenance and function in aging. Semin Immunol. 2012;24(5):342\u20139. https:\/\/doi.org\/10.1016\/j.smim.2012.04.004.","journal-title":"Semin Immunol"},{"issue":"5","key":"2136_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/ejh.13839","volume":"109","author":"CY Soekojo","year":"2022","unstructured":"Soekojo CY, Chng WJ. The evolution of immune dysfunction in multiple myeloma. Eur J Haematol. 2022;109(5):415\u201324. https:\/\/doi.org\/10.1111\/ejh.13839.","journal-title":"Eur J Haematol"},{"key":"2136_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3389\/fonc.2014.00348","volume":"4","author":"C Botta","year":"2014","unstructured":"Botta C, Gull\u00e0 A, Correale P, Tagliaferri P, Tassone P. Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol. 2014;4:348. https:\/\/doi.org\/10.3389\/fonc.2014.00348.","journal-title":"Front Oncol"},{"issue":"7","key":"2136_CR23","doi-asserted-by":"publisher","first-page":"e2208692","DOI":"10.1002\/adma.202208692","volume":"35","author":"Z Liu","year":"2023","unstructured":"Liu Z, Zhang J, Liu H, Shen H, Meng N, Qi X, Ding K, Song J, Fu R, Ding D, Feng G. BSA-AIE nanoparticles with boosted ROS generation for immunogenic cell death immunotherapy of multiple myeloma. Adv Mater. 2023;35(7):e2208692. https:\/\/doi.org\/10.1002\/adma.202208692.","journal-title":"Adv Mater"},{"issue":"1","key":"2136_CR24","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"SM Tirier","year":"2021","unstructured":"Tirier SM, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021;12(1):6960. https:\/\/doi.org\/10.1038\/s41467-021-26951-z.","journal-title":"Nat Commun"},{"issue":"17","key":"2136_CR25","doi-asserted-by":"publisher","first-page":"9298","DOI":"10.3390\/ijms22179298","volume":"22","author":"A Kulikowska de Na\u0142\u0119cz","year":"2021","unstructured":"Kulikowska de Na\u0142\u0119cz A, et al. Deregulated expression of immune checkpoints on circulating CD4 T cells may complicate clinical outcome and response to treatment with checkpoint inhibitors in multiple myeloma patients. Int J Mol Sci. 2021;22(17):9298. https:\/\/doi.org\/10.3390\/ijms22179298.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2136_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.20517\/cdr.2021.116","volume":"5","author":"A Gozzetti","year":"2022","unstructured":"Gozzetti A, et al. Drug resistance and minimal residual disease in multiple myeloma. Cancer Drug Resist. 2022;5(1):171\u201383. https:\/\/doi.org\/10.20517\/cdr.2021.116.","journal-title":"Cancer Drug Resist"},{"key":"2136_CR27","doi-asserted-by":"publisher","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","volume":"48","author":"S Narayanan","year":"2020","unstructured":"Narayanan S, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updates Rev Comment Antimicrob Anticancer Chemother. 2020;48:100663. https:\/\/doi.org\/10.1016\/j.drup.2019.100663.","journal-title":"Drug Resist Updates Rev Comment Antimicrob Anticancer Chemother"},{"issue":"9","key":"2136_CR28","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kort\u00fcm","year":"2016","unstructured":"Kort\u00fcm KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226\u201333. https:\/\/doi.org\/10.1182\/blood-2016-02-698092.","journal-title":"Blood"},{"issue":"68","key":"2136_CR29","doi-asserted-by":"publisher","first-page":"112917","DOI":"10.18632\/oncotarget.22872","volume":"8","author":"E Bertrand","year":"2017","unstructured":"Bertrand E, Jouy N, Manier S, et al. Role of IRF4 in resistance to immunomodulatory (IMid) compounds\u00ae in Waldenstr\u00f6m\u2019s macroglobulinemia. Oncotarget. 2017;8(68):112917\u201327. https:\/\/doi.org\/10.18632\/oncotarget.22872.","journal-title":"Oncotarget"},{"issue":"1","key":"2136_CR30","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","volume":"13","author":"YLD Ng","year":"2022","unstructured":"Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, M\u00fcller S, Popp O, Kull M, Haji M, G\u00fctschow M, D\u00f6hner H, Walther W, Keller U, Bullinger L, Mertins P, Kr\u00f6nke J. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022;13(1):1009. https:\/\/doi.org\/10.1038\/s41467-022-28515-1.","journal-title":"Nat Commun"},{"issue":"16","key":"2136_CR31","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1073\/pnas.0305855101","volume":"101","author":"PW Derksen","year":"2004","unstructured":"Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargaren M, Pals ST. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA. 2004;101(16):6122\u20137. https:\/\/doi.org\/10.1073\/pnas.0305855101.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2136_CR32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959\u201370. https:\/\/doi.org\/10.1182\/blood-2016-03-703439.","journal-title":"Blood"},{"issue":"10","key":"2136_CR33","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2015.123","volume":"29","author":"IS Nijhof","year":"2015","unstructured":"Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein SK, Martens AC, Doshi P, Sasser K, Mutis T, van de Donk NW. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039\u201349. https:\/\/doi.org\/10.1038\/leu.2015.123.","journal-title":"Leukemia"},{"issue":"15","key":"2136_CR34","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/bloodadvances.2021004176","volume":"5","author":"N Gazeau","year":"2021","unstructured":"Gazeau N, Beauvais D, Yakoub-Agha I, Mitra S, Campbell TB, Facon T, Manier S. Effective anti-BCMA retreatment in multiple myeloma. Blood Adv. 2021;5(15):3016\u201320. https:\/\/doi.org\/10.1182\/bloodadvances.2021004176.","journal-title":"Blood Adv"},{"issue":"6","key":"2136_CR35","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","volume":"36","author":"J O'Neal","year":"2022","unstructured":"O\u2019Neal J, Ritchey JK, Cooper ML, Niswonger J, Sof\u00eda Gonz\u00e1lez L, Street E, Rettig MP, Gladney SW, Gehrs L, Abboud R, Prior JL, Haas GJ, Jayasinghe RG, Ding L, Ghobadi A, Vij R, DiPersio JF. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. Leukemia. 2022;36(6):1625\u201334. https:\/\/doi.org\/10.1038\/s41375-022-01559-4.","journal-title":"Leukemia"},{"issue":"1","key":"2136_CR36","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","volume":"13","author":"ID Ferguson","year":"2022","unstructured":"Ferguson ID, Pati\u00f1o-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG 3rd, Shah N, Wiita AP. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun. 2022;13(1):4121. https:\/\/doi.org\/10.1038\/s41467-022-31810-6.","journal-title":"Nat Commun"},{"key":"2136_CR37","doi-asserted-by":"publisher","first-page":"106742","DOI":"10.1016\/j.phrs.2023.106742","volume":"190","author":"A Zinzi","year":"2023","unstructured":"Zinzi A, et al. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: a definite evidence from systematic review and meta-analysis on individual data. Pharmacol Res. 2023;190:106742. https:\/\/doi.org\/10.1016\/j.phrs.2023.106742.","journal-title":"Pharmacol Res"},{"issue":"5","key":"2136_CR38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nri3433","volume":"13","author":"H Geiger","year":"2013","unstructured":"Geiger H, de Haan G, Florian MC. The ageing haematopoietic stem cell compartment. Nat Rev Immunol. 2013;13(5):376\u201389. https:\/\/doi.org\/10.1038\/nri3433.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2136_CR39","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1084\/jem.147.5.1526","volume":"147","author":"DE Harrison","year":"1978","unstructured":"Harrison DE, Astle CM, Delaittre JA. Loss of proliferative capacity in immunohemopoietic stem cells caused by serial transplantation rather than aging. J Exp Med. 1978;147(5):1526\u201331. https:\/\/doi.org\/10.1084\/jem.147.5.1526.","journal-title":"J Exp Med"},{"issue":"6","key":"2136_CR40","doi-asserted-by":"publisher","first-page":"a041197","DOI":"10.1101\/cshperspect.a041197","volume":"14","author":"A Singh","year":"2024","unstructured":"Singh A, Schurman SH, Bektas A, Kaileh M, Roy R, Wilson DM 3rd, Sen R, Ferrucci L. Aging and Inflammation. Cold Spring Harb Perspect Med. 2024;14(6):a041197. https:\/\/doi.org\/10.1101\/cshperspect.a041197.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"2136_CR41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/s41416-019-0721-1","volume":"122","author":"E Laconi","year":"2020","unstructured":"Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. Br J Cancer. 2020;122(7):943\u201352. https:\/\/doi.org\/10.1038\/s41416-019-0721-1.","journal-title":"Br J Cancer"},{"issue":"1","key":"2136_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2136_CR43","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jgo.2016.07.013","volume":"7","author":"T Hsu","year":"2016","unstructured":"Hsu T. Educational initiatives in geriatric oncology - who, why, and how? J Geriatr Oncol. 2016;7(5):390\u20136. https:\/\/doi.org\/10.1016\/j.jgo.2016.07.013.","journal-title":"J Geriatr Oncol"},{"key":"2136_CR44","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fimmu.2018.00586","volume":"9","author":"IM Rea","year":"2018","unstructured":"Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586. https:\/\/doi.org\/10.3389\/fimmu.2018.00586.","journal-title":"Front Immunol"},{"key":"2136_CR45","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev-immunol-020711-075008","volume":"30","author":"G Trinchieri","year":"2012","unstructured":"Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30:677\u2013706. https:\/\/doi.org\/10.1146\/annurev-immunol-020711-075008.","journal-title":"Annu Rev Immunol"},{"key":"2136_CR46","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860\u20137. https:\/\/doi.org\/10.1038\/nature01322.","journal-title":"Nature"},{"key":"2136_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/biology9120485","author":"L Cuollo","year":"2020","unstructured":"Cuollo L, Antonangeli F, Santoni A, Soriani A. The senescence-associated secretory phenotype (Sasp) in the challenging future of cancer therapy and age-related diseases. Biology (Basel). 2020. https:\/\/doi.org\/10.3390\/biology9120485.","journal-title":"Biology (Basel)"},{"issue":"1","key":"2136_CR48","doi-asserted-by":"publisher","first-page":"e12848","DOI":"10.1111\/acel.12848","volume":"18","author":"PFL da Silva","year":"2019","unstructured":"da Silva PFL, Ogrodnik M, Kucheryavenko O, Glibert J, Miwa S, Cameron K, Ishaq A, Saretzki G, Nagaraja-Grellscheid S, Nelson G, von Zglinicki T. The bystander effect contributes to the accumulation of senescent cells in vivo. Aging Cell. 2019;18(1):e12848. https:\/\/doi.org\/10.1111\/acel.12848.","journal-title":"Aging Cell"},{"key":"2136_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0804-8","author":"L Yang","year":"2019","unstructured":"Yang L, Li A, Lei Q, Zhang Y. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. J Hematol Oncol. 2019. https:\/\/doi.org\/10.1186\/s13045-019-0804-8.","journal-title":"J Hematol Oncol"},{"key":"2136_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00986-z","author":"J Lian","year":"2020","unstructured":"Lian J, Yue Y, Yu W, Zhang Y. Immunosenescence: a key player in cancer development. J Hematol Oncol. 2020. https:\/\/doi.org\/10.1186\/s13045-020-00986-z.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2136_CR51","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3322\/caac.21577","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Miller KD, Dale W, Mohile SG, Cohen HJ, Leach CR, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin. 2019;69(6):452\u201367. https:\/\/doi.org\/10.3322\/caac.21577.","journal-title":"CA Cancer J Clin"},{"key":"2136_CR52","doi-asserted-by":"publisher","first-page":"584683","DOI":"10.3389\/fonc.2020.584683","volume":"10","author":"H Fairfield","year":"2021","unstructured":"Fairfield H, Costa S, Falank C, Farrell M, Murphy CS, D\u2019Amico A, Driscoll H, Reagan MR. Multiple myeloma cells alter adipogenesis, increase senescence-related and inflammatory gene transcript expression, and alter metabolism in preadipocytes. Front Oncol. 2021;10:584683. https:\/\/doi.org\/10.3389\/fonc.2020.584683.","journal-title":"Front Oncol"},{"issue":"5","key":"2136_CR53","doi-asserted-by":"publisher","first-page":"e13344","DOI":"10.1111\/acel.13344","volume":"20","author":"RI Mart\u00ednez-Zamudio","year":"2021","unstructured":"Mart\u00ednez-Zamudio RI, Dewald HK, Vasilopoulos T, Gittens-Williams L, Fitzgerald-Bocarsly P, Herbig U. Senescence-associated \u03b2-galactosidase reveals the abundance of senescent CD8+ T cells in aging humans. Aging Cell. 2021;20(5):e13344. https:\/\/doi.org\/10.1111\/acel.13344.","journal-title":"Aging Cell"},{"key":"2136_CR54","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fonc.2020.00636","volume":"10","author":"N Leblay","year":"2020","unstructured":"Leblay N, Maity R, Hasan F, Neri P. Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities. Front Oncol. 2020;10:636. https:\/\/doi.org\/10.3389\/fonc.2020.00636.","journal-title":"Front Oncol"},{"issue":"10","key":"2136_CR55","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.4049\/jimmunol.1403158","volume":"194","author":"MJ Kim","year":"2015","unstructured":"Kim MJ, Miller CM, Shadrach JL, Wagers AJ, Serwold T. Young, proliferative thymic epithelial cells engraft and function in aging thymuses. J Immunol. 2015;194(10):4784\u201395. https:\/\/doi.org\/10.4049\/jimmunol.1403158.","journal-title":"J Immunol"},{"issue":"9","key":"2136_CR56","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/ncb3023","volume":"16","author":"N Bredenkamp","year":"2014","unstructured":"Bredenkamp N, Ulyanchenko S, O\u2019Neill KE, Manley NR, Vaidya HJ, Blackburn CC. An organized and functional thymus generated from FOXN1-reprogrammed fibroblasts. Nat Cell Biol. 2014;16(9):902\u20138. https:\/\/doi.org\/10.1038\/ncb3023.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"2136_CR57","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1182\/blood-2010-09-307983","volume":"117","author":"Z Keren","year":"2011","unstructured":"Keren Z, Naor S, Nussbaum S, Golan K, Itkin T, Sasaki Y, Schmidt-Supprian M, Lapidot T, Melamed D. B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. Blood. 2011;117(11):3104\u201312. https:\/\/doi.org\/10.1182\/blood-2010-09-307983.","journal-title":"Blood"},{"key":"2136_CR58","doi-asserted-by":"publisher","first-page":"14533","DOI":"10.1038\/ncomms14533","volume":"8","author":"M Wahlestedt","year":"2017","unstructured":"Wahlestedt M, Erlandsson E, Kristiansen T, Lu R, Brakebusch C, Weissman IL, Yuan J, Martin-Gonzalez J, Bryder D. Clonal reversal of ageing-associated stem cell lineage bias via a pluripotent intermediate. Nat Commun. 2017;8:14533. https:\/\/doi.org\/10.1038\/ncomms14533.","journal-title":"Nat Commun"},{"issue":"2","key":"2136_CR59","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2666-7568(20)30011-8","volume":"1","author":"LS Cox","year":"2020","unstructured":"Cox LS, Bellantuono I, Lord JM, Sapey E, Mannick JB, Partridge L, Gordon AL, Steves CJ, Witham MD. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. Lancet Healthy Longev. 2020;1(2):e55\u20137. https:\/\/doi.org\/10.1016\/S2666-7568(20)30011-8.","journal-title":"Lancet Healthy Longev"},{"issue":"20","key":"2136_CR60","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma. J Clin Oncol. 2022;40(20):2246\u201356. https:\/\/doi.org\/10.1200\/JCO.21.01676.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2136_CR61","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","volume":"38","author":"C Li","year":"2024","unstructured":"Li C, Xu J, Luo W, Liao D, Xie W, Wei Q, Zhang Y, Wang X, Wu Z, Kang Y, Zheng J, Xiong W, Deng J, Hu Y, Mei H. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Leukemia. 2024;38(1):149\u201359. https:\/\/doi.org\/10.1038\/s41375-023-02065-x.","journal-title":"Leukemia"},{"issue":"1","key":"2136_CR62","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","volume":"41","author":"Y Tang","year":"2022","unstructured":"Tang Y, Yin H, Zhao X, Jin D, Liang Y, Xiong T, Li L, Tang W, Zhang J, Liu M, Yu Z, Liu H, Zang S, Huang Z. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J Exp Clin Cancer Res. 2022;41(1):2. https:\/\/doi.org\/10.1186\/s13046-021-02214-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"2136_CR63","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.1200\/JCO.2023.41.16_suppl.8005","volume":"41","author":"J Du","year":"2023","unstructured":"Du J, Fu W-J, Jiang H, Dong B, Gao L, Liu L, et al. Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8005.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2136_CR64","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fern\u00e1ndez de Larrea","year":"2020","unstructured":"Fern\u00e1ndez de Larrea C, Staehr M, Lopez AV, Ng KY, Chen Y, Godfrey WD, Purdon TJ, Ponomarev V, Wendel HG, Brentjens RJ, Smith EL. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 2020;1(2):146\u201354. https:\/\/doi.org\/10.1158\/2643-3230.BCD-20-0020.","journal-title":"Blood Cancer Discov"},{"issue":"12","key":"2136_CR65","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-20-0118","volume":"8","author":"A Globerson Levin","year":"2020","unstructured":"Globerson Levin A, Rawet Slobodkin M, Waks T, Horn G, Ninio-Many L, Deshet Unger N, Ohayon Y, Suliman S, Cohen Y, Tartakovsky B, Naparstek E, Avivi I, Eshhar Z. Treatment of multiple myeloma using chimeric antigen receptor T cells with dual specificity. Cancer Immunol Res. 2020;8(12):1485\u201395. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0118.","journal-title":"Cancer Immunol Res"},{"key":"2136_CR66","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood-2021-152160","volume":"138","author":"M Vrohlings","year":"2021","unstructured":"Vrohlings M, M\u00fcller J, Jungmichel S, Senn D, Howald AB, Schleier T, et al. Preclinical assessment of CDR101 - a BCMAxCD3xPD-L1 trispecific antibody with superior anti-tumor efficacy. Blood. 2021;138:1583. https:\/\/doi.org\/10.1182\/blood-2021-152160.","journal-title":"Blood"},{"key":"2136_CR67","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/blood-2022-159353","volume":"140","author":"M Pihlgren","year":"2022","unstructured":"Pihlgren M, Hall O, Carretero L, Estoppey C, Drake A, Pais D, et al. ISB 2001, a first-in-class trispecific BCMA and CD38 T cell engager designed to overcome mechanisms of escape from treatments for multiple myeloma by targeting two antigens. Blood. 2022;140:858\u20139. https:\/\/doi.org\/10.1182\/blood-2022-159353.","journal-title":"Blood"},{"issue":"1","key":"2136_CR68","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/s41467-024-46310-y","volume":"15","author":"C Grandcl\u00e9ment","year":"2024","unstructured":"Grandcl\u00e9ment C, Estoppey C, Dheilly E, Panagopoulou M, Monney T, Dreyfus C, Loyau J, Labanca V, Drake A, De Angelis S, Rubod A, Frei J, Caro LN, Blein S, Martini E, Chimen M, Matthes T, Kaya Z, Edwards CM, Edwards JR, Sammicheli S. Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma. Nat Commun. 2024;15(1):2054. https:\/\/doi.org\/10.1038\/s41467-024-46310-y.","journal-title":"Nat Commun"},{"issue":"3","key":"2136_CR69","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/JCO.21.02815","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol. 2023;41(3):568\u201378. https:\/\/doi.org\/10.1200\/JCO.21.02815.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2136_CR70","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36(4):561\u201384. https:\/\/doi.org\/10.1007\/s10555-017-9707-8.","journal-title":"Cancer Metastasis Rev"},{"issue":"30","key":"2136_CR71","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","volume":"28","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa AM, Hulin C, Facon T, Attal M, Minvielle S, Harousseau JL. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630\u20134. https:\/\/doi.org\/10.1200\/JCO.2010.28.3945.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2136_CR72","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bbmt.2009.11.025","volume":"16","author":"P Nemec","year":"2010","unstructured":"Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, Tajtlova J, Kralova D, Kupska R, Smetana J, Krejci M, Pour L, Zahradova L, Sandecka V, Adam Z, Buchler T, Spicka I, Gregora E, Kuglik P, Hajek R. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant. 2010;16(4):548\u201354. https:\/\/doi.org\/10.1016\/j.bbmt.2009.11.025.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2136_CR73","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2141.2008.07454.x","volume":"144","author":"T Sutlu","year":"2009","unstructured":"Sutlu T, Alici E, Jansson M, Wallblom A, Dilber MS, Gahrton G, Nahi H. The prognostic significance of 8p21 deletion in multiple myeloma. Br J Haematol. 2009;144(2):266\u20138. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07454.x.","journal-title":"Br J Haematol"},{"issue":"3","key":"2136_CR74","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s12185-014-1514-1","volume":"99","author":"N Sekiguchi","year":"2014","unstructured":"Sekiguchi N, Ootsubo K, Wagatsuma M, Midorikawa K, Nagata A, Noto S, Yamada K, Takezako N. Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib\/dexamethasone therapy. Int J Hematol. 2014;99(3):288\u201395. https:\/\/doi.org\/10.1007\/s12185-014-1514-1.","journal-title":"Int J Hematol"},{"issue":"4","key":"2136_CR75","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ajh.23387","volume":"88","author":"TS Hawley","year":"2013","unstructured":"Hawley TS, Riz I, Yang W, Wakabayashi Y, Depalma L, Chang YT, Peng W, Zhu J, Hawley RG. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 2013;88(4):265\u201372. https:\/\/doi.org\/10.1002\/ajh.23387.","journal-title":"Am J Hematol"},{"issue":"2","key":"2136_CR76","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/leu.2017.212","volume":"32","author":"A Besse","year":"2018","unstructured":"Besse A, Stolze SC, Rasche L, Weinhold N, Morgan GJ, Kraus M, Bader J, Overkleeft HS, Besse L, Driessen C. Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia. 2018;32(2):391\u2013401. https:\/\/doi.org\/10.1038\/leu.2017.212.","journal-title":"Leukemia"},{"issue":"38","key":"2136_CR77","doi-asserted-by":"publisher","first-page":"40496","DOI":"10.18632\/oncotarget.5800","volume":"6","author":"R Franqui-Machin","year":"2015","unstructured":"Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget. 2015;6(38):40496\u2013506. https:\/\/doi.org\/10.18632\/oncotarget.5800.","journal-title":"Oncotarget"},{"issue":"1","key":"2136_CR78","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4252\/wjsc.v7.i1.84","volume":"7","author":"I Saltarella","year":"2015","unstructured":"Saltarella I, Lamanuzzi A, Reale A, Vacca A, Ria R. Identify multiple myeloma stem cells: Utopia? World J Stem Cells. 2015;7(1):84\u201395. https:\/\/doi.org\/10.4252\/wjsc.v7.i1.84.","journal-title":"World J Stem Cells"},{"issue":"8","key":"2136_CR79","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1182\/blood-2013-02-482919","volume":"122","author":"Y Yang","year":"2013","unstructured":"Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, Zhou W, Zhou Y, Das S, Gu Z, Levasseur D, Zhan F, Tricot G. RAR\u03b12 expression confers myeloma stem cell features. Blood. 2013;122(8):1437\u201347. https:\/\/doi.org\/10.1182\/blood-2013-02-482919.","journal-title":"Blood"},{"issue":"6168","key":"2136_CR80","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke J, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301\u20135. https:\/\/doi.org\/10.1126\/science.1244851.","journal-title":"Science"},{"issue":"6168","key":"2136_CR81","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305\u20139. https:\/\/doi.org\/10.1126\/science.1244917.","journal-title":"Science"},{"issue":"1","key":"2136_CR82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22\u201332. https:\/\/doi.org\/10.1038\/leu.2009.236.","journal-title":"Leukemia"},{"issue":"1","key":"2136_CR83","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","volume":"62","author":"K Luptakova","year":"2013","unstructured":"Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013;62(1):39\u201349. https:\/\/doi.org\/10.1007\/s00262-012-1308-3.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2136_CR84","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","volume":"58","author":"C Galustian","year":"2009","unstructured":"Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58(7):1033\u201345. https:\/\/doi.org\/10.1007\/s00262-008-0620-4.","journal-title":"Cancer Immunol Immunother"},{"key":"2136_CR85","doi-asserted-by":"publisher","first-page":"924058","DOI":"10.1155\/2011\/924058","volume":"2011","author":"YT Tai","year":"2011","unstructured":"Tai YT, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011;2011:924058. https:\/\/doi.org\/10.1155\/2011\/924058.","journal-title":"Bone Marrow Res"},{"issue":"1","key":"2136_CR86","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","volume":"12","author":"B Yu","year":"2019","unstructured":"Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12(1):94. https:\/\/doi.org\/10.1186\/s13045-019-0786-6.","journal-title":"J Hematol Oncol"},{"key":"2136_CR87","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/1538-7445.AM2011-770","volume":"71","author":"A Skaletskaya","year":"2011","unstructured":"Skaletskaya A, Setiady YY, Park PU, Lutz RJ. Abstract 770: Lorvotuzumab mertansine (IMGN901) immune effector activity and its effect on human NK cells. Cancer Res. 2011;71:770. https:\/\/doi.org\/10.1158\/1538-7445.AM2011-770.","journal-title":"Cancer Res"},{"issue":"20","key":"2136_CR88","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128\u201338. https:\/\/doi.org\/10.1182\/blood-2013-10-535088.","journal-title":"Blood"},{"key":"2136_CR89","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1182\/blood-2019-129652","volume":"134","author":"Z Shah","year":"2019","unstructured":"Shah Z, Malik MN, Batool SS, Kotapati S, Akhtar A, Rehman O, Ghani M, Sadiq M, Akbar A, Ashraf A, et al. Bispecific T-cell engager (BiTE) antibody based immunotherapy for treatment of relapsed refractory multiple myeloma (RRMM): a systematic review of preclinical and clinical trials. Blood. 2019;134:5567. https:\/\/doi.org\/10.1182\/blood-2019-129652.","journal-title":"Blood"},{"issue":"4","key":"2136_CR90","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3324\/haematol.2020.266841","volume":"108","author":"X Zhou","year":"2023","unstructured":"Zhou X, Rasche L, Kort\u00fcm KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2023;108(4):958\u201368. https:\/\/doi.org\/10.3324\/haematol.2020.266841.","journal-title":"Haematologica"},{"issue":"1","key":"2136_CR91","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868. https:\/\/doi.org\/10.1038\/s41467-021-21177-5.","journal-title":"Nat Commun"},{"issue":"2","key":"2136_CR92","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","volume":"29","author":"C Amatya","year":"2021","unstructured":"Amatya C, Pegues MA, Lam N, Vanasse D, Geldres C, Choi S, Hewitt SM, Feldman SA, Kochenderfer JN. Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7. Mol Ther. 2021;29(2):702\u201317. https:\/\/doi.org\/10.1016\/j.ymthe.2020.10.008.","journal-title":"Mol Ther"},{"issue":"2","key":"2136_CR93","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ymthe.2023.12.018","volume":"32","author":"L Mikkilineni","year":"2024","unstructured":"Mikkilineni L, Natrakul DA, Lam N, Manasanch EE, Mann J, Weissler KA, Wong N, Brudno JN, Goff SL, Yang JC, Ganaden M, Patel R, Zheng Z, Gartner JJ, Martin KR, Wang HW, Yuan CM, Lowe T, Maric I, Shao L, Kochenderfer JN. Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain. Mol ther. 2024;32(2):503\u201326. https:\/\/doi.org\/10.1016\/j.ymthe.2023.12.018.","journal-title":"Mol ther"},{"issue":"5","key":"2136_CR94","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/bjh.19346","volume":"204","author":"M Mohty","year":"2024","unstructured":"Mohty M, Bahlis NJ, Nooka AK, DiBonaventura M, Ren J, Conte U. Impact of elranatamab on quality of life: patient-reported outcomes from MagnetisMM-3. Br J Haematol. 2024;204(5):1801\u201310. https:\/\/doi.org\/10.1111\/bjh.19346.","journal-title":"Br J Haematol"},{"issue":"9","key":"2136_CR95","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodr\u03afguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Mohty M. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"issue":"11","key":"2136_CR96","doi-asserted-by":"publisher","first-page":"e007803","DOI":"10.1136\/jitc-2023-007803","volume":"11","author":"SY Lee","year":"2023","unstructured":"Lee SY, Lee DH, Sun W, Cervantes-Contreras F, Basom RS, Wu F, Liu S, Rai R, Mirzaei HR, O\u2019Steen S, Green DJ, Shadman M, Till BG. CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype. J Immunother Cancer. 2023;11(11):e007803. https:\/\/doi.org\/10.1136\/jitc-2023-007803.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2136_CR97","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","volume":"9","author":"T Martin","year":"2022","unstructured":"Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, Hari P, Berdeja JG, Usmani SZ, Yeh TM, Olyslager Y, Goldberg JD, Schecter JM, Madduri D, Jackson CC, Deraedt W, Gries KS, Fastenau JM, Trudeau JJ, Akram M, Jagannath S. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\u20132, open-label study. Lancet Haematol. 2022;9(12):e897\u2013905. https:\/\/doi.org\/10.1016\/S2352-3026(22)00284-8.","journal-title":"Lancet Haematol"},{"issue":"10297","key":"2136_CR98","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O\u2019Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"issue":"23","key":"2136_CR99","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kort\u00fcm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Lonial S. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer. 2023;129(23):3746\u201360. https:\/\/doi.org\/10.1002\/cncr.34987.","journal-title":"Cancer"},{"issue":"11","key":"2136_CR100","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1007\/s12325-021-01884-7","volume":"38","author":"T Prawitz","year":"2021","unstructured":"Prawitz T, Popat R, Suvannasankha A, Sarri G, Hughes R, Wang F, Hogea C, Ferrante SA, Gorsh B, Willson J, Kapetanakis V. DREAMM-2: indirect comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and standard of care treatments in relapsed\/refractory multiple myeloma. Adv Ther. 2021;38(11):5501\u201318. https:\/\/doi.org\/10.1007\/s12325-021-01884-7.","journal-title":"Adv Ther"},{"issue":"2","key":"2136_CR101","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kort\u00fcm KM, Rodr\u00edguez-Otero P, Usmani SZ, Cohen AD. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(19)30788-0.","journal-title":"Lancet Oncol"},{"issue":"288","key":"2136_CR102","doi-asserted-by":"publisher","first-page":"288ra78","DOI":"10.1126\/scitranslmed.aaa7014","volume":"7","author":"KA Noonan","year":"2015","unstructured":"Noonan KA, Huff CA, Davis J, Lemas MV, Fiorino S, Bitzan J, Ferguson A, Emerling A, Luznik L, Matsui W, Powell J, Fuchs E, Rosner GL, Epstein C, Rudraraju L, Ambinder RF, Jones RJ, Pardoll D, Borrello I. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015;7(288):288ra78. https:\/\/doi.org\/10.1126\/scitranslmed.aaa7014.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2136_CR103","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-13-2817","volume":"20","author":"AP Rapoport","year":"2014","unstructured":"Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, June CH. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3\/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res. 2014;20(5):1355\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2817.","journal-title":"Clin Cancer Res"},{"key":"2136_CR104","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","volume":"38","author":"S Mailankody","year":"2020","unstructured":"Mailankody S, et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020;38:8504\u20138504. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.8504.","journal-title":"J Clin Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02136-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02136-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02136-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T17:06:02Z","timestamp":1743267962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02136-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2136"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02136-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"402"}}